Here's what happened in life sciences last week 💊📰

FDA wants to shorten new drug monopolies, AI to find kidney disease, innovation in Egypt and other interesting reads from the past week.

Noteworthy 📰

  • Five key takeaways from the world's largest cancer research conference. Link

  • J&J faces high-stakes trial over 22 women's talc claims. Link

  • A blood-based cancer test gets its first results. Link

  • Diabetes giant Novo Nordisk may be considering thousands of job cuts. Link

  • FDA wants to shorten new drug monopolies to cut costs. Link

Digital Health 💻

  • We told Siri, Google and Alexa we were having suicidal thoughts -- and here's what they said. Link

  • See how this hospital uses AI to find kidney disease. Link

  • Headspace aims to be first FDA-approved prescription meditation app. Link

Research 🔬

  • This fungus could help cure cancer. Link

  • Doctors hail world first as woman’s advanced breast cancer is eradicated. Link

  • New technology could enable remote control of drug delivery, sensing. Link

Perspective and Opinions 📢

  • Will probiotics ever live up to the hype? Link

  • Why Egypt is at the forefront of Hepatitis C treatment? Link

Interesting 🤔

Deep Drive 👓

Artificial Intelligence could prevent tens of thousands of deaths a year and take pressure off national health systems, but privacy campaigners are worried.

Notable Startups 💰

Nimbus Therapeutics, a biotech company pioneering the application of computational technologies to the design and development of novel treatments for substantial and underserved human diseases, secured $65m in funding

Just Biotherapeutics, a Shanghai, China-based developer of global antibody and recombinant protein biotherapeutics, raised 35m in Series B+ financing round.

nference, provider of an artificial intelligence (AI)-powered life sciences software platform, completed an $11m Series A financing.

Genetesis, a medical device company focused on using biomagnetic imaging to enable rapid, noninvasive and accurate chest pain triage, closed $7.5M Series A financing.

Enyo Pharma, a France-based clinical stage biotech company developing innovative drug candidates by mimicking virus strategies to modulate host cellular functions, completed a €40m in Series B financing.

Our Digital Times 😃